Congestive Heart Failure
Conditions
Keywords
congestive heart failure, Brain naturietic peptide, hospital utilization cost
Brief summary
Measurement of brain natriuretic peptide (BNP) in dyspneic patients increases diagnostic accuracy for congestive heart failure (CHF). Limited information is available regarding economic outcomes attributable to BNP assay. The aim of this study was to assess the economic impact of BNP assay in elderly dyspneic patients presenting to the emergency department (ED).
Detailed description
Dyspneic patients 65 years were enrolled in a randomized, controlled trial; hemodynamically unstable patients were excluded. BNP (Biosite assay) levels were measured prior to physician assessment with randomization in 1:1 ratio to either BNP 1) level reported or 2) level not reported. ED physicians made triage decisions guided by clinical judgment and nomogram to aid in interpretation of BNP level. Primary outcome was mean total hospital cost per subject. Secondary outcomes included admission rate, service assignment, discharge diagnosis and length of stay. Differences between groups were compared by t-test with bootstrap. Costs reflect 2005 constant dollars.
Interventions
None listed
Sponsors
Mayo Clinic
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Dyspneic patients 65 years or older presenting to the ED with chief complaint of shortness of breath.
Exclusion criteria
* hemodynamically unstability
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean total hospital cost per subject | spans from ED eval through hospitalization discharge |
Secondary
| Measure | Time frame |
|---|---|
| Included admission rate, service assignment, discharge diagnosis, and length of stay. | from ED evaluation through hospitalization discharge |
Countries
United States
Outcome results
None listed